PharmiWeb Recruiter Blog

$14.4 million commitment from Lilly will focus on strengthening health care for children and adolescents living with and at risk of non-communicable diseases

Women’s health company, Organon, is giving all its employees a day off on 8^th March and is issuing a call to action to all employers in the UK to join forces and do the same

California’s Life Science industry provides more than 1.37 million jobs across the state, and in 2020, generated more than $405 billion in Total Business Sales. Using data from Biocom California, we’ve rounded up these key figures that represent the scale of California’s Life Science job market.

Parenteral and device manufacturing site will increase the number of people around the world who may benefit from Lilly's medicines

• Invyxis to leverage Dalriada’s agile Turn-Key^TMmodel to establish and rapidly advance a pipeline of NCEs in mental health 

This strategic collaboration with atai Life...

One of the biggest challenges for Life Science recruiters is how to keep candidates engaged throughout the recruitment process. In recent years, LinkedIn has reported a 20% increase in job seeker drop off from the process, and with the current job market becoming even more competitive, reducing this drop off is key in securing the best talent in 2022.

• Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia
• Collaboration with Syneos Health to effectively reach the primary care market in Europe and Canada

Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022
Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health^® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada.

Technology is set to play a much bigger role in the healthcare industry in 2022, with advancements taking effect quicker than ever before. In this article, we’ve put together predictions from 4 industry experts on what we can expect from the healthcare industry in 2022…

• PARTNERSHIP LEVERAGES EVOTEC’S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS 
• AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS

Hamburg 25 January 2022:
Evotec announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (“iPSC”)-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. 

Through phenotypic screening of human iPSC-derived cells, supported by Evotec’s PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions. Boehringer Ingelheim will then continue with the discovery and development of potential therapeutic candidates. Besides an undisclosed upfront and FTE-based research payment, Evotec will continue to benefit from the successful further development of the candidates in the form of milestones and layered royalties.

Vetter Development Service Rankweil receives manufacturing authorization